Tumour suppressor Fus1 provides a molecular link between inflammatory response and mitochondrial homeostasis

Journal of Pathology

Volumn 227, Issue 4, 2012, Pages 456-469

  Uzhachenko, Roman ^a   Issaeva, Natalia ^a   Boyd, Kelli ^b   Ivanov, Sergey V ^a   Carbone, David P ^a   Ivanova, Alla V ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

asbestos; DN T cells; Fus1; inflammatory response; mitochondria; mitochondrial membrane potential; ROS; UCP2

Indexed keywords

ASBESTOS; GAMMA INTERFERON; HISTONE H2AX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEAR PROTEIN; PEROXIREDOXIN 1; PROTEIN GAMMA H2AX; RANTES; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CONTROLLED STUDY; FUS1 GENE; GENE EXPRESSION; GRANULOCYTE; IMMUNOCOMPETENT CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; ORGAN WEIGHT; PERITONEAL FLUID; PERITONEUM CELL; PERITONEUM MACROPHAGE; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; T LYMPHOCYTE SUBPOPULATION; TUMOR SUPPRESSOR GENE; WILD TYPE;

EID: 84863715552     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4039     Document Type: Article

References (93)

1. Reuter S, Gupta SC, Chaturvedi MM, et al., Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010; 49 (11): 1603-1616.
2. Naik E, Dixit VM,. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med 2011; 208: 417-420.
3. West AP, Shadel GS, Ghosh S,. Mitochondria in innate immune responses. Nat Rev Immunol 2011; 11: 389-402.
4. Case AJ, McGill JL, Tygrett LT, et al., Elevated mitochondrial superoxide disrupts normal T cell development, impairing adaptive immune responses to an influenza challenge. Free Radic Biol Med 2011; 50: 448-458.
5. Krysko DV, Agostinis P, Krysko O, et al., Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32: 157-164.
6. Ivanova AV, Ivanov SV, Pascal V, et al., Autoimmunity, spontaneous tumourigenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1. J Pathol 2007; 211: 591-601.
7. Wistuba II, Behrens C, Virmani AK, et al., High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60: 1949-1960.
8. Ivanova AV, Ivanov SV, Prudkin L, et al., Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer 2009; 8: 91-107.
9. Prudkin L, Behrens C, Liu DD, et al., Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res 2008; 14: 41-47.
10. 1 arrest and growth inhibition of lung cancer cells. Oncogene 2001; 20: 6258-6262.
11. Uno F, Sasaki J, Nishizaki M, et al., Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res 2004; 64: 2969-2976.
12. Ito I, Ji L, Tanaka F, et al., Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004; 11: 733-739.
13. Ji L, Roth JA,. Tumor suppressor FUS1 signaling pathway. J Thorac Oncol 2008; 3: 327-330.
14. Lin J, Sun T, Ji L, et al., Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 2007; 26: 6989-6996.
15. Deng WG, Kawashima H, Wu G, et al., Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res 2007; 67: 709-717.
16. Deng WG, Wu G, Ueda K, et al., Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Cancer Gene Ther 2008; 15: 29-39.
17. Gottlieb E, Tomlinson IP,. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005; 5: 857-866.
18. Liu Y, Borchert GL, Donald SP, et al., Proline oxidase functions as a mitochondrial tumor suppressor in human cancers. Cancer Res 2009; 69: 6414-6422.
19. Kim HS, Patel K, Muldoon-Jacobs K, et al., SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17: 41-52.
20. Seth RB, Sun L, Ea CK, et al., Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-ΰB and IRF 3. Cell 2005; 122: 669-682.
21. Hou F, Sun L, Zheng H, et al., MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 2011; 146 (3): 448-461.
22. Tschopp J,. Mitochondria: Sovereign of inflammation? Eur J Immunol 2011; 41: 1196-1202.
23. 2+ and ROS take center stage to orchestrate TNFα-mediated inflammatory responses. J Clin Invest; 121: 1683-1685.
24. Shukla A, Gulumian M, Hei TK, et al., Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med 2003; 34: 1117-1129.
25. Poland CA, Duffin R, Kinloch I, et al., Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 2008; 3: 423-428.
26. +/- mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 2008; 33: 105-116.
27. Palomaki J, Valimaki E, Sund J, et al., Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. ACS Nano 2011; 5: 6861-6870.
28. Sabo-Attwood T, Ramos-Nino ME, Eugenia-Ariza M, et al., Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis. Am J Pathol 2011; 178: 1975-1985.
29. Hillegass JM, Shukla A, Lathrop SA, et al., Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann NY Acad Sci 2010; 1203: 7-14.
30. Dostert C, Petrilli V, Van Bruggen R, et al., Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320: 674-677.
31. Mossman BT, Churg A,. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998; 157: 1666-1680.
32. Hill GD, Mangum JB, Moss OR, et al., Soluble ICAM-1, MCP-1, and MIP-2 protein secretion by rat pleural mesothelial cells following exposure to amosite asbestos. Exp Lung Res 2003; 29: 277-290.
33. Choe N, Tanaka S, Xia W, et al., Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ Health Perspect 1997; 105 (suppl 5): 1257-1260.
34. Yang H, Rivera Z, Jube S, et al., Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 2010; 107: 12611-12616.
35. Donaldson K, Murphy FA, Duffin R, et al., Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010; 7: 5.
36. Cullen RT, Searl A, Miller BG, et al., Pulmonary and intraperitoneal inflammation induced by cellulose fibres. J Appl Toxicol 2000; 20: 49-60.
37. Philip M, Rowley DA, Schreiber H,. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004; 14: 433-439.
38. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-867.
39. Lawrence T,. Inflammation and cancer: a failure of resolution? Trends Pharmacol Sci 2007; 28: 162-165.
40. Rodriguez-Vita J, Lawrence T,. The resolution of inflammation and cancer. Cytokine Growth Factor Rev 2010; 21: 61-65.
41. Robledo RF, Buder-Hoffmann SA, Cummins AB, et al., Increased phosphorylated extracellular signal-regulated kinase immunoreactivity associated with proliferative and morphologic lung alterations after chrysotile asbestos inhalation in mice. Am J Pathol 2000; 156: 1307-1316.
42. Cummins AB, Palmer C, Mossman BT, et al., Persistent localization of activated extracellular signal-regulated kinases (ERK1/2) is epithelial cell-specific in an inhalation model of asbestosis. Am J Pathol 2003; 162: 713-720.
43. Manning CB, Sabo-Attwood T, Robledo RF, et al., Targeting the MEK1 cascade in lung epithelium inhibits proliferation and fibrogenesis by asbestos. Am J Respir Cell Mol Biol 2008; 38: 618-626.
44. Barlow CA, Barrett TF, Shukla A, et al., Asbestos-mediated CREB phosphorylation is regulated by protein kinase A and extracellular signal-regulated kinases 1/2. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1361-1369.
45. Ortiz BD, Nelson PJ, Krensky AM,. Switching gears during T-cell maturation: RANTES and late transcription. Immunol Today 1997; 18: 468-471.
46. Song A, Nikolcheva T, Krensky AM,. Transcriptional regulation of RANTES expression in T lymphocytes. Immunol Rev 2000; 177: 236-245.
47. Otsuki T, Maeda M, Murakami S, et al., Immunological effects of silica and asbestos. Cell Mol Immunol 2007; 4: 261-268.
48. Miller LG, Sparrow D, Ginns LC,. Asbestos exposure correlates with alterations in circulating T cell subsets. Clin Exp Immunol 1983; 51: 110-116.
49. El, Hentati FZ, Gruy F, Iobagiu C, et al., Variability of CD3 membrane expression and T cell activation capacity. Cytom B Clin Cytom 2010; 78: 105-114.
50. Illes Z, Waldner H, Reddy J, et al., Modulation of CD4 co-receptor limits spontaneous autoimmunity when high-affinity transgenic TCR specific for self-antigen is expressed on a genetically resistant background. Int Immunol 2007; 19: 1235-1248.
51. Rousset S, Emre Y, Join-Lambert O, et al., The uncoupling protein 2 modulates the cytokine balance in innate immunity. Cytokine 2006; 35: 135-142.
52. Emre Y, Nubel T,. Uncoupling protein UCP2: when mitochondrial activity meets immunity. FEBS Lett 2010; 584: 1437-1442.
53. 2+- and redox-dependent production of nitric oxide. J Immunol 2003; 171: 5188-5197.
54. Gergely P Jr, Niland B, Gonchoroff N, et al., Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol 2002; 169: 1092-1101.
55. Li G, Kawashima H, Ji L, et al., Frequent absence of tumor suppressor FUS1 protein expression in human bone and soft tissue sarcomas. Anticancer Res 2011; 31: 11-21.
56. Lerman MI, Minna JD,. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000; 60: 6116-6133.
57. Ogawa Y, Duru EA, Ameredes BT,. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med 2008; 8: 437-445.
58. Koya T, Takeda K, Kodama T, et al., RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge. Am J Respir Cell Mol Biol 2006; 35: 147-154.
59. Grayson MH, Holtzman MJ,. Chemokine complexity: the case for CCL5. Am J Respir Cell Mol Biol 2006; 35: 143-146.
60. Ivanova AV, Goparaju CM, Ivanov SV, et al., Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma. Clin Cancer Res 2009; 15: 2602-2611.
61. Lapteva N, Huang XF,. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther 2010; 10: 725-733.
62. Chen W, Ford MS, Young KJ, et al., The role and mechanisms of double negative regulatory T cells in the suppression of immune responses. Cell Mol Immunol 2004; 1: 328-335.
63. Thomson CW, Lee BP, Zhang L,. Double-negative regulatory T cells: non-conventional regulators. Immunol Res 2006; 35: 163-178.
64. - double-negative T cells in peripheral blood of children with Behcet's disease. Autoimmun Rev 2007; 6: 237-240.
65. Ford MS, Chen W, Wong S, et al., Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development. Eur J Immunol 2007; 37: 2234-2241.
66. Sieling PA, Porcelli SA, Duong BT, et al., Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J Immunol 2000; 165: 5338-5344.
67. Crispin JC, Oukka M, Bayliss G, et al., Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181: 8761-8766.
68. - T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol 2001; 100: 314-324.
69. Young KJ, DuTemple B, Phillips MJ, et al., Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol 2003; 171: 134-141.
70. + T cells in murine cytomegalovirus infection. Immunology 2000; 101: 19-29.
71. - T cells differentiate extrathymically in an lck-independent manner and participate in early response against Listeria monocytogenes infection through interferon-γ production. Immunology 1997; 91: 511-519.
72. - T cells and cytokine serum levels in young and adult rats. Exp Parasitol 2007; 116: 366-374.
73. + T cells and display an inflammatory effector phenotype. J Immunol 2009; 183: 4675-4681.
74. + T cells. J Immunol 2008; 181: 440-448.
75. + T cell precursors. J Immunol 2006; 177: 2803-2809.
76. - T cells in autoimmune-prone non-obese diabetic mice. Immunol Cell Biol 2010; 88: 771-780.
77. - double-negative T cells. Eur J Immunol 2011; 41: 739-748.
78. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
79. Beyer M, Schultze JL,. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
80. Wang Y, Huang L, Abdelrahim M, et al., Stanniocalcin-1 suppresses superoxide generation in macrophages through induction of mitochondrial UCP2. J Leukoc Biol 2009; 86: 981-988.
81. Gatza E, Wahl DR, Opipari AW, et al., Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med 2011; 3: 67ra68.
82. Abarca-Rojano E, Muniz-Hernandez S, Moreno-Altamirano MM, et al., Reorganization of mitochondria at the NK cell immune synapse. Immunol Lett 2009; 122: 18-25.
83. Sanchez-Cenizo L, Formentini L, Aldea M, et al., Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H + -ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem 2010; 285: 25308-25313.
84. Goodglick LA, Kane AB,. Cytotoxicity of long and short crocidolite asbestos fibers in vitro and in vivo. Cancer Res 1990; 50: 5153-5163.
85. Kamp DW, Panduri V, Weitzman SA, et al., Asbestos-induced alveolar epithelial cell apoptosis: role of mitochondrial dysfunction caused by iron-derived free radicals. Mol Cell Biochem 2002; 234-235: 153-160.
86. Panduri V, Weitzman SA, Chandel N, et al., The mitochondria-regulated death pathway mediates asbestos-induced alveolar epithelial cell apoptosis. Am J Respir Cell Mol Biol 2003; 28: 241-248.
87. Arsenijevic D, Onuma H, Pecqueur C, et al., Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet 2000; 26: 435-439.
88. Galluzzi L, Morselli E, Kepp O, et al., Mitochondrial gateways to cancer. Mol Aspects Med 2010; 31: 1-20.
89. Acharya A, Das I, Chandhok D, et al., Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 2010; 3: 23-34.
90. Grek CL, Tew KD,. Redox metabolism and malignancy. Curr Opin Pharmacol 2010; 10: 362-368.
91. Pani G, Galeotti T, Chiarugi P,. Metastasis: cancer cells' escape from oxidative stress. Cancer Metast Rev 2010; 29: 351-378.
92. Lee KW, Lee HJ,. Biphasic effects of dietary antioxidants on oxidative stress-mediated carcinogenesis. Mech Ageing Dev 2006; 127: 424-431.
93. Schins RP, Knaapen AM,. Genotoxicity of poorly soluble particles. Inhal Toxicol 2007; 19 (suppl 1): 189-198.